Juvéderm Voluma XC Receives FDA Approval for Age-Related Volume Loss in the Cheek

Allergan, the maker of Juvéderm Voluma™ XC has announced that the company has received approval from the U.S. Food and Drug Administration (FDA) to market the injectable as the first and only facial filler approved to temporarily correct age-related volume loss in the cheek area in adults over the age of 21.

According to an Allergan press release, Juvéderm Voluma™ XC helps create a more youthful appearance to the face and provides natural-looking and long-lasting results up to two years with optimal treatment.

"As people age, the cheek area can lose volume, causing the cheeks to flatten out and the skin to droop and sag," said Dr. Derek H. Jones, associate professor of dermatology, UCLA, founder and medical director, Skin Care and Laser Physicians of Beverly Hills, and clinical investigator in the filler's clinical trial where "physicians and patients were able to see instant and visible results, including correction of age-related volume loss in the cheek area and a more youthful appearance to the face."

Dr. Hamori has been offering Juvéderm for many years as a reliable and popular facial filler, and now has this new product specifically developed for the cheek area.

For more information, please see the press release on FDA approval and Dr. Hamori's page on Juvéderm Voluma XC.

Christine Hamori Cosmetic Surgery + Skin Spa
113 Tremont Street, Duxbury, Massachusetts, 02332
Tel. 781-934-2200
Serving Boston's South Shore, Cape Cod and Nantucket